Who are Silence Therapeutics plc's main suppliers?

Silence Therapeutics plc (SLN) key suppliers include: AstraZeneca PLC, AstraZeneca PLC, HANSOH-PHARMACEUTICAL-GROUP-COMPANY-LIMITED, JEFFERIES-LLC, MALLINCKRODT-PLC and 2 more. View the full supplier network at chainsifter.com/chain/SLN.

Who are Silence Therapeutics plc's major customers?

Silence Therapeutics plc (SLN) key customers include: AstraZeneca PLC, AstraZeneca PLC, ALL-WALES-MEDICINES-STRATEGY-GROUP, COORDINATION-GROUP, LEASES-THE-GROUP. View the full customer network at chainsifter.com/chain/SLN.

What sector is Silence Therapeutics plc in?

Silence Therapeutics plc (SLN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Silence Therapeutics plc Supplier List (SLN): 7 Verified Suppliers

7Suppliers

5Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Silence Therapeutics plc (SLN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

13Total relationships

3Distinct source URLs

6High confidence

0.772Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Silence Therapeutics plc Suppliers

Ticker	Name	Confidence	Evidence
AZN	AstraZeneca PLC	90%	Reciprocal relationship from AZN graph: Reciprocal relationship from SLN graph: Under this agreement, AstraZeneca made an upfront cash payment to us of $20.0 million in May 2020.
AZN	AstraZeneca PLC	90%	Under this agreement, AstraZeneca made an upfront cash payment to us of $20.0 million in May 2020.
HANSOH-PHARMACEUTICAL-GROUP-COMPANY-LIMITED	HANSOH-PHARMACEUTICAL-GROUP-COMPANY-LIMITED	90%	In the past, we have entered into collaborations with other parties, including pharmaceutical and biotechnology companies like Hansoh Pharmaceutical Group Company Limited, or Hansoh, and AstraZeneca …
JEFFERIES-LLC	JEFFERIES-LLC	90%	Under the Sales Agreement, the Company may offer and sell, from time to time, through Jefferies as its sales agent and/or principal, American Depositary Shares of the Company
MALLINCKRODT-PLC	MALLINCKRODT-PLC	80%	In March 2024, Mallinckrodt notified us that they will not pursue further development of SLN501
ALNY	Alnylam Pharmaceuticals, Inc.	72%	Reciprocal relationship from ALNY graph: Reciprocal relationship from SLN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from SLN graph: Reciprocal relationship from ALNY gra…
BDRX	Biodexa Pharmaceuticals Plc	72%	Reciprocal relationship from BDRX graph: ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized …

Silence Therapeutics plc Customers

Ticker	Name	Confidence	Evidence
AZN	AstraZeneca PLC	72%	the Group’s operating leases at December 31, 2024: Fiscal year Operating Leases 2025 117 2026 - 2027 - 2028 - 2029 - Thereafter - Total expected lease payments 117 Less: Imputed interest - Total leas…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from SLN graph: Reciprocal relationship from AZN graph: Reciprocal relationship from SLN graph: the Group’s operating leases at Decembe…
ALL-WALES-MEDICINES-STRATEGY-GROUP	ALL-WALES-MEDICINES-STRATEGY-GROUP	62%	2030. Selected high-risk medical devices will also be assessed under the HTA Regulation as of 2026. The HTA Regulation is intended to harmonize the clinical benefit assessment of HTA across the EU an…
COORDINATION-GROUP	COORDINATION-GROUP	62%	ices resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute…
LEASES-THE-GROUP	LEASES-THE-GROUP	62%	onsideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Group must make significant judgments, includi…

Silence Therapeutics plc Debt Obligations

Instrument	Description	Confidence	Evidence
SLN-DEBT	Debt stack $136,000	90%	Market cache reports total debt of $136,000.

Silence Therapeutics plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Silence Therapeutics plc.

Silence Therapeutics plc Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Silence Therapeutics plc.

Silence Therapeutics plc Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
DRTS	Alpha Tau Medical Ltd.	100.00	2
TNXP	Tonix Pharmaceuticals Holding Corp.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
IDYA	IDEAYA Biosciences, Inc.	100.00	2
VEEV	Veeva Systems Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	1	['customer', 'supplier']
NVO	Novo Nordisk A/S	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
DEO	Diageo plc	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	1	['supplier']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	1	['supplier']
SRPT	Sarepta Therapeutics, Inc.	100.00	2

Silence Therapeutics plc Supply Chain